Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Stimulation of Toll-like receptors (TLR) by pathogen-derived compounds leads to activation of APC, facilitating the induction of protective immunity. This phenomenon is the basis of most adjuvant formulations currently in development. Here, we tested the ability of TLR2, 3, 4, 5, 7 and 9 signaling to enhance CTL responses upon vaccination with virus-like particles. Stimulation of TLR2 and 4 failed to increase CTL responses, whereas ligands for TLR3, 5 and 7 exhibited moderate adjuvant function. In contrast, stimulation of TLR9 dramatically increased CTL responses, indicating that ligands for TLR9 are likely to be the most promising candidates for the development of novel adjuvant formulations for stimulating CTL responses.

Original publication

DOI

10.1002/eji.200323919

Type

Journal article

Journal

Eur J Immunol

Publication Date

06/2003

Volume

33

Pages

1465 - 1470

Keywords

Adjuvants, Immunologic, Aminoquinolines, Animals, Antigens, CD, Antigens, Viral, B7-1 Antigen, B7-2 Antigen, CpG Islands, Cytotoxicity, Immunologic, DNA-Binding Proteins, Dendritic Cells, Female, Flagellin, Glycoproteins, Hepatitis B Core Antigens, Humans, Imiquimod, Lipopolysaccharides, Membrane Glycoproteins, Mice, Mice, Inbred C57BL, Oligodeoxyribonucleotides, Peptide Fragments, Receptors, Cell Surface, Signal Transduction, T-Lymphocytes, Cytotoxic, Toll-Like Receptor 2, Toll-Like Receptor 3, Toll-Like Receptor 6, Toll-Like Receptor 9, Toll-Like Receptors, Vaccination, Viral Proteins